HK2 and neoplasm: To validate observations in EOC cell lines in vitro, we found that CDDP treatment significantly enhances the nuclear accumulation of HKII-P-p53 (Ser15) both in primary human EOC cultures/ascites and in tumor sections with platinum-sensitive cancers, defined by a PFI > 6 months.